paradigms in drug development. Functionally, a privileged structure is a 23 molecular scaffold that can accommodate various pharmacophores arranged to 24 promote interaction with biological targets{Costantino, 2006 #1; Evans, 1988 25 #74; Horton, 2003 #3; Maclean, 2000 #2}. While many have been synthetically 26 designed, nature remains the largest source of highly sophisticated biologically 27 active privileged compounds because presumably they play a key role in 28 increasing the survival fitness of an organism{Koehn, 2005 #75; Maplestone, 29 1992 #76; Williams, 1989 #77}. In fact, about one-third of the ~980 new 30 pharmaceuticals in the past two and a half decades originated from or were 31 inspired by natural products{Newman, 2007 #5}. 32 With over 10,000 structurally characterized members, plant alkaloids are 33 important privileged compounds from which many key clinical medicines are 34 derived ( Table 1) {Beghyn, 2008 #4; Facchini, 2008 #13; Kutchan, 1995 #6; 35 Verpoorte, 2000 #11}. The endogeneous role of alkaloids in plants has not been 36 fully elucidated. However, current evidence suggests that alkaloids are generally 37 involved in plant defense against pathogens, insects, and herbivores due to their 38 potent toxicity{Hartmann, 2004 #12}. For example, the indolizidine, indolizine, 39 and -carbolines paradigmatic alkaloid backbone structures can exert over 25 40 biological activities, such as dopamine reuptake inhibitor, glucosidase inhibitor, 41 sodium channel blocker, and 5HT1D agonist{Beghyn, 2008 #4}. The bioactivities 42 of alkaloids have been recognized and exploited since ancient human civilization, 43 from the utilization of Conium maculatum (hemlock) extract containing the 44 neurotoxin alkaloid coniine to poison Socrates, to the use of caffeine in coffee 45 and tea as a mild stimulant{Kutchan, 1995 #6}. Today, numerous alkaloids are 46 pharmacologically well-characterized and used as clinical drugs, ranging from cancer chemotherapeutics to analgesic agents ( Table 1) . 48
Despite their importance, the inefficiency of extracting some alkaloids 49 remains a significant barrier towards inexpensive bioprospecting for drug 50 development. The process of separating, purifying, and structurally 51 characterizing compounds of interest from a myriad of other metabolites is time-52 consuming and expensive. Bioactive alkaloids are also usually present in small 53 quantities ( Table 1) . Furthermore, the yield consistency can not always be 54 guaranteed because it depends heavily on the source organisms as well as 55 geographical and climate conditions. The scarcity of some alkaloids in plants is 56 exemplified by the cancer chemotherapeutic compound vincristine, which is 57 found in Catharanthus roseus at concentrations that only reach 0.0003% by dry 58 weight{Kuboyama, 2004 #9}. 59
The field of organic synthesis has advanced tremendously in the past 60 decades in creating various methodologies suitable for constructing bisindole 61 alkaloids with multiple functionalities and stereocenters{Kuboyama, 2004 #9; 62 Miyazaki, 2007 #7; Uchida, 2006 #8; Yokoshima, 2002 #10}. Nevertheless, total 63 or semi-synthesis of many other alkaloids remains a daunting challenge that is 64 far from being practical at the industrial level. Plant tissue and cell cultures can 65 serve as alternative production platforms in which the biosynthesis of alkaloids 66 has been improved through various elicitation and culture manipulation 67 strategies. Additionally, supported by the availability of systems biology datasets, 68 metabolic engineering now has the potential to more effectively maximize the 69 capacity for alkaloid biosynthesis in cellular systems. For the most part, major 70 advancements in alkaloid metabolic engineering occurred within the last decade. 71
In this Perspective, we first focus on the milestones and challenges in 72 engineering plant tissue and cell lines for improving natural alkaloid production, 73 and for facilitating the synthesis of unnatural alkaloids. Recently, there has been 74 an increasing interest in the engineering of microorganisms for the synthesis of 75 high-value metabolites. To this end, we highlight the recent construction of 76 artificial alkaloid biosynthetic pathways in Escherichia coli and Saccharomyces 77 cerevisiae and discuss the potential for the use of microbes as novel alkaloid 78 production platforms. 79 80 Alkaloid biosynthetic pathway elucidation and manipulation in plants 81
82
The significance of alkaloids has motivated the characterization of their 83 biosynthetic pathways. Mechanistic elucidation of enzymatic steps typically 84 begins by tracking isotopically labeled metabolites in differentiated plants or plant 85 cell cultures. Further steps commonly involve reverse genetics where, following 86 plant enzyme isolation and purification, partial sequence data of the purified 87 protein is used to obtain the corresponding gene from a cDNA library. This allows 88 the identification of the starting substrates, and enables the proposal of a series 89 of logical biosynthetic transformations. Recently, genomic and transcriptomic 6 technologies have been used to rapidly identify biosynthetic steps. There are 91 currently over 40,000 expressed enzyme tags (ESTs) generated from alkaloid 92 producing plants that have been used to isolate genes involved in the alkaloid 93 pathway{Facchini, 2008 #13}. Nevertheless, the availability of genome 94 sequences of alkaloid producer plants is urgently needed to further speed the 95 elucidation of their biosynthesis. To date, the biosynthetic routes of four alkaloid As with whole-plant systems, the intricate relationships among metabolic 218 pathways and regulatory schemes in plant cells and tissues are among the many 219 factors that limit the robustness of a metabolic engineering design to achieve a 220 specific overproduction target. Various systems biology approaches have been 221 developed to portray the complex metabolic interplay in plant tissue and cell 222 systems. In one instance, flux analysis using isotopomer{Schwender, 2004 #46; 223 Schwender, 2004 #47}, and 'bond-isomer'{Sriram, 2007 #48; Sriram, 2004 #49} 224 labeling and balancing has been employed to profile flux distribution in the 225 central metabolism of C. roseus hairy roots. Significant progress has also been 226 made towards elucidating the genome-wide interconnectivity among biological 227 functions resulting in datasets that contain gene-to gene and gene-to-metabolite 228 networks that reveal regulatory differences in key alkaloid pathways in C. roseus 229 cells{Rischer, 2006 #28}. Alkaloid metabolic regulatory machineries have also 230 been probed by using transcriptome analysis, leading to the identification of 231 several transcription factors in MIA biosynthesis{van der Fits, 2000 #30; Menke, 232 1999 #31}. All together, this information can potentially be useful in determining 233 metabolic engineering targets that can effectively deliver a desired improvement 234 in a specific alkaloid branch pathway. For instance, a metabolic engineering 235 strategy to increase MIA production was devised to exploit the utility of the 236 ORCA3 transcription factor to upregulate the expression of many MIA 237 biosynthetic genes simultaneously{van der Fits, 2000 #30}. However, initial 238
ORCA3 overexpression in C. roseus cell cultures did not significantly improve 239 MIA synthesis. It was discovered that even though ORCA3 positively regulates 240 the expression of many genes that lead to the synthesis of strictosidine, it does 241 not up-regulate the expression of geraniol 10-hydroxylase (G10H), the enzyme in 242 the terpenoid pathway that leads to the synthesis of secologanin. Upon 243 supplemental feeding of the secologanin precursor, loganin, the overexpression 244 of ORCA3 resulted in ~3-fold increase of MIA biosynthesis. Another 245 transcriptome study revealed the complexity of MIA biosynthetic control by a 246 variety of transcriptional regulators. In this case, it was discovered that although 247 the MIA biosynthetic enzymes that were upregulated upon ORCA3 248 overexpression in C. roseus hairy root lines is similar to those in cell lines, the 249 transcriptional repressors ZCT1 and ZCT2 were also upregulated{Peebles, 2008 containing a D177A mutation that exhibited increased selectivity towards a 279 secologanin analog with a pentynyl group was identified. This strategy clearly 280 demonstrated the benefit of re-engineering STR plasticity for mutasynthetic 281 purposes. However, the ability to explore a widely diverse mutational space was 282 still limited due to the lack of a facile screening assay. In approaching this 283 challenge, a medium-throughput colorimetric assay was developed in order to 284 identify functional STR mutants that can accept tryptamine analogs{Bernhardt, 285 2007 #54}. The medium-throughput assay took advantage of the formation of 286 products downstream of STR that can be visualized when metabolized by 287 strictosidine glucosidase (SG). By applying a saturation mutagenesis strategy on 288 several residues that form the tryptamine binding pocket, two STR mutants 289 (V214M, F232L) that turned over unnatural tryptamine compounds to synthesize 290 -carboline analogs were identified using the in vitro assay{Loris, 2007 #78}. 291
When the newly synthesized strictosidine analogs were fed to C. roseus hairy 292 root cultures, a number of novel MIA analogs were obtained (Scheme 2). This is the inability to produce certain alkaloids due to the lack of specialized cell 406 types{St-Pierre, 1999 #70}. For instance, vincristine and vinblastine are not 407 significantly produced in C. roseus cell suspension and hairy root cultures 408 because the vindoline precursor pathway is only fully activated in aerial plant 409 parts{Bhadra, 1993 #72; Shanks, 1998 #71}. Metabolic reconstruction will 410 therefore be required for increasing the utility of plant cell lines and tissues for 411 commercial production systems, and necessitate the enrichment and 412 development of robust genetic tools for plant transformation. Similar to whole 413 plant systems however, the existence of multiple alkaloid biosynthetic pathways, 414 regulatory control mechanisms, and pathway compartmentalization are among 415 the factors that significantly increase the degree of unpredictability of metabolic 416 engineering efforts (Fig. 1a) . The lack of complete understanding of the complex 417 alkaloid biosynthetic networks also hinders the determination of an effective 418 metabolic engineering strategy to achieve a specific production phenotype. Microbes are even more scalable than plant tissue and cell cultures, with a 428 long and successful history as chemical factories for the large-scale production of 429 both bulk and specialized chemical products. The degree of complexity in 430 microorganisms is significantly less than that of plant systems (Fig. 1b) , such 431 that the lack of preexisting branch alkaloid pathways and transcription factors in 432 microbes should also simplify the choice of metabolic engineering targets and 433 approaches. The recent demonstrations of engineering alkaloid pathways in microbes are promising, but are limited by the need to provide expensive 435 intermediate precursors exogenously. The complete elucidation of alkaloid 436 biosynthesis from simple precursors can facilitate the construction of the 437 upstream pathway in microbes, hence avoiding the necessity of providing 438 expensive intermediates. However, this strategy will likely entail the implantation 439 of numerous biosynthetic steps, which is not trivial. For example, the 440 reconstruction of the plant (S)-reticuline biosynthetic pathway from tyrosine will 441 involve at least 7 enzymes. There are several other challenges that must be met 442 before microorganisms can be used as an industrial alkaloid production platform. 443
For example, because many steps in alkaloid biosynthesis require methylation, 444
high-level production in microbial systems will likely be limited by the intracellular 445 availability of S-adenosyl-L-methionine (SAM). Therefore, this bottleneck 446 motivates further metabolic engineering efforts to increase the SAM pool in the 447 microbial host. The cytotoxicity of alkaloids in yeast has also been 448 implicated{Geerlings, 2001 #32}, and is presumably a factor in other microbes as 449 well. Therefore, practical and effective strategies need to be devised to mitigate 450 toxicity in order to generate alkaloid overproducing microbes. A transcriptomic 451 approach has been recently used to diagnose the effect of metabolite toxicity, 452 and resulted in a strategy to dampen the impact of the toxicity on growth 453 inhibition{Kizer, 2008 #82}. Moreover, a new strategy to increase microbial 454 tolerance towards toxic metabolites by engineering transcription factors{Alper,
In conclusion, although both plant cell/tissue and microbial systems offer 457 tremendous advantages as scalable alkaloid production platforms, many 458 opportunities still lie in cellular and metabolic engineering sectors to create the 459 multifaceted phenotypic traits (e.g. high productivity, product tolerance, stability) 460 required for use in industrial bioprocesses. Moreover, because the characteristics 461 between plant cell/tissue and microbial systems are inherently different, they can 462 serve as complimentary unit operations when cleverly integrated together in 463 biomanufacturing in order to solve the long-standing problem of robust alkaloid 464 production. 465
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